Abstract Library

#2109 Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ali A

Authors: Ali A, Grönberg M, Hjortland G, Grønbæk H, Ladekarl M,

Keywords: chemotherapy, Neuroendocrine Neoplasms, Intravenous, Oral, survival,

#1455 Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)

Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Ali A, Grönberg M, Federspiel B, Hjortland G, Ladekarl M,

Keywords: Neuroendocrine Carcinoma, mutation, p53, overall survival,

#1298 Temozolomide-based Second-line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours

Introduction: The management of advanced Bronchopulmonary Neuroendocrine Tumours (BP-NET) is not standardized. There are only few clinical studies of Temozolomide (TMZ) as monotherapy or in combination with other agents available for BP-NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tabaksblat E, Ladekarl M,

Keywords: temozolomide, BP-NET, Ki-67 index,